April 30 Company Quick Takes: Merck, G1, Pfizer, Amgen and more

Merck sales rise in China

Merck & Co. Inc. (NYSE:MRK) said product sales in China were $725 million for 1Q19, up 67% on an ex-exchange basis from 1Q18 and driven by products in its vaccines and oncology businesses. On its earnings conference call Tuesday, Chief Commercial Officer Frank Clyburn said the pharma hopes that Keytruda pembrolizumab will be added to China's National Reimbursement Drug List this year.

G1 planning 2020 NDA

Read the full 696 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE